Delivery Order HHSO100201700023I-75A50122F61001

Award Date 3/8/22
Potential Completion Date 12/7/23
Potential Value $756K
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Albuquerque, NM 87108, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,711,752.76 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The order is part of the Biomedical Advanced Research and Development Authority's (BARDA) Biological Animal Model Development 2017-2022 contract vehicle and involves the development of animal models for evaluating medical countermeasures against...
This is a $1,764,756.57 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The order was issued under the Biomedical Advanced Research and Development Authority (BARDA) Chem and RadNuc Animal Model 2015-2020 IDIQ contract. The purpose is to conduct a non-primate animal model study on host biomarker...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $716,374 delivery order contract to Lovelace Biomedical Research Institute. Under the terms of the firm fixed price contract, Lovelace Biomedical Research Institute will conduct a Good Laboratory Practice repeat dose toxicology study for BPL-24910 in support of the Comprehensive and Rapid Response for NIAID Research Programs major program code. Performance...
This federal contract award was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The $1,211,007.00 delivery order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of the Lovelace Biomedical Research Institute. The contract is a cost-plus-fixed-fee arrangement under the Biomedical Advanced Research and Development Authority...
This is a federal contract award to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization, by the Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract, valued at $3,717,268.00, is for the performance verification of institutional radiation dose response for acute radiation syndrome (ARS) animal models, including rodents, rabbits, minipigs, and non-human primates. This is a delivery order contract with a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $486,301.00 cost-plus-fixed-fee delivery order contract to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. Under this contract, the Lovelace Biomedical Research Institute will perform the transfer, validation, and qualification of bioanalytical methods for the detection of cabotegravir and levonorgestrel in rat and nonhuman primate plasma. This work is being conducted...
This is a task order contract award to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization, by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS). The contract, valued at $57,500.00, is for management support activities related to the BIO-AMT-2301 Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle. This vehicle supports ASPR with a wide...
This federal contract award is for a Delivery Order under the National Institute of Allergy and Infectious Diseases (NIAID) Animal Models of Infectious Diseases 2010-2017 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. The $1,513,255.77 cost-plus-fixed-fee contract was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute, to provide a non-human primate model for testing the immunogenicity and...
This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS). The contract, valued at $401,001.96, was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order under the "BARDA Chem and RadNuc Animal Model 2015-2020" Indefinite Delivery/Indefinite...
This is a task order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization. The task order, titled "PRE-CLINICAL MODELS OF INFECTIOUS DISEASES TASK ORDER B07", is part of NIAID's Preclinical Models of Infectious Diseases contract vehicle, which provides...

This is a cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Lovelace Biomedical Research Institute, a non-profit preclinical contract research organization. The $756,111 award supports non-clinical immunogenicity studies of SARS-CoV-2 microneedle patch vaccine candidates in a small-animal model. This work is being performed under ASPR's Biological Animal Model Development 2017-2022 IDIQ contract. Lovelace Biomedical Research Institute has supported numerous federal agencies through both contracts and grants, leveraging its expertise in animal modeling and preclinical product development across areas like infectious diseases, drug discovery, and medical countermeasures. The award does not utilize a set-aside designation.

Generated 6/25/24, 1:41 PM